Importance of ROS1 gene fusions in non-small cell lung cancer

Abstract

Targeted therapy has become one of the standards of care for advanced lung cancer. More than 10 genetic aberrations have been discovered that are actionable and several tyrosine kinase inhibitors (TKIs) have been approved to target each of them. Among several genetic aberrations that are actionable in non-small cell lung cancer (NSCLC), ROS1 translocations also known as gene fusion proteins, are found in only 1%-2% of the patient population. ROS1 mutations can usually be detected using a combination of techniques such as immunohistochemistry (IHC), Fluorescence in-situ testing (FISH), polymerase chain reaction (PCR), and next-generation sequencing (NGS). However, RNA NGS and ctDNA NGS (liquid biopsies) also contribute to the diagnosis. There are currently numerous FDA-approved agents for these tumors, including crizotinib and entrectinib; however, there is in-vitro sensitivity data and clinical data documenting responses to ceritinib and lorlatinib. Clinical responses and survival rates with these agents are frequently among the best compared to other TKIs with genetic aberrations; however, intrinsic or extrinsic mechanisms of resistance may develop, necessitating research for alternative treatment modalities. To combat the mechanisms of resistance, novel agents such as repotrectenib, cabozantinib, talotrectinib, and others are being developed. In this article, we examine the literature pertaining to patients with ROS1 tumors, including epidemiology, clinical outcomes, resistance mechanisms, and treatment options.

Keywords

ROS1 / targeted therapy / non-small cell lung cancer

References

[1] Cancer Statistics. Available from: https://www.cancer.gov/about-cancer/understanding/statistics. [Last accessed on 5 Jun 2023]

[2] SEER Cancer Stat Facts: Lung and bronchus cancer. Available from: https://seer.cancer.gov/statfacts/html/lungb.html. [Last accessed on 5 Jun 2023]

[3] Yang JC,Schuler M.Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.Lancet Oncol2015;16:141-51

[4] Rosell R,Gervais R.Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia ToracicaErlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.Lancet Oncol2012;13:239-46

[5] Charest A,Park J.Oncogenic targeting of an activated tyrosine kinase to the Golgi apparatus in a glioblastoma.Proc Natl Acad Sci USA2003;100:916-21 PMCID:PMC298701

[6] Matsushime H,Shibuya M.Human c-ros-1 gene homologous to the v-ros sequence of UR2 sarcoma virus encodes for a transmembrane receptorlike molecule.Mol Cell Biol1986;6:3000-4 PMCID:PMC367872

[7] Birchmeier C,Wigler M.Expression and rearrangement of the ROS1 gene in human glioblastoma cells.Proc Natl Acad Sci USA1987;84:9270-4 PMCID:PMC299735

[8] Marinelli D,Metro G,Gelibter AJ.Non-small-cell lung cancer: how to manage ALK-, ROS1- and NTRK-rearranged disease.Drugs Context2022;11:1-16 PMCID:PMC9576009

[9] Abbosh C,Wilson GA.TRACERx consortiumPEACE consortiumCharles SwantonPhylogenetic ctDNA analysis depicts early-stage lung cancer evolution.Nature2017;545:446-51 PMCID:PMC5812436

[10] Sung H,Siegel RL.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2021;71:209-49

[11] Siegel RL,Jemal A.Cancer statistics, 2020.CA Cancer J Clin2020;70:7-30

[12] Gainor JF.Novel targets in non-small cell lung cancer: ROS1 and RET fusions.Oncologist2013;18:865-75 PMCID:PMC3720641

[13] Talukdar S,Das SK.EGFR: an essential receptor tyrosine kinase-regulator of cancer stem cells.Adv Cancer Res2020;147:161-88

[14] Siegel RL,Fuchs HE.Cancer Statistics, 2021.CA Cancer J Clin2021;71:7-33

[15] Ianza A,Biagi C.EGFR mutation analysis on circulating free DNA in NSCLC: a single-center experience.J Cancer Res Clin Oncol2021;147:2301-7 PMCID:PMC8236477

[16] Takeuchi K,Togashi Y.RET, ROS1 and ALK fusions in lung cancer.Nat Med2012;18:378-81

[17] Kawaguchi T,Ando M.Prospective analysis of oncogenic driver mutations and environmental factors: Japan molecular epidemiology for lung cancer study.J Clin Oncol2016;34:2247-57

[18] Soria JC,Vansteenkiste J.FLAURA InvestigatorsOsimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer.N Engl J Med2018;378:113-25

[19] Chevallier M,Addeo A.Oncogenic driver mutations in non-small cell lung cancer: past, present and future.World J Clin Oncol2021;12:217-37 PMCID:PMC8085514

[20] Pikor LA,Lam S.Genetic alterations defining NSCLC subtypes and their therapeutic implications.Lung Cancer2013;82:179-89

[21] Shaw AT.Targeting anaplastic lymphoma kinase in lung cancer.Clin Cancer Res2011;17:2081-6

[22] Peters S,Shaw AT.ALEX Trial InvestigatorsAlectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer.N Engl J Med2017;377:829-38

[23] Wolf J,Han JY.GEOMETRY mono-1 InvestigatorsCapmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer.N Engl J Med2020;383:944-57

[24] Drilon A,Tan DSW.Efficacy of Selpercatinib in RET fusion-positive non-small-cell lung cancer.N Engl J Med2020;383:813-24 PMCID:PMC7506467

[25] Gainor JF,Kim DW.Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.Lancet Oncol2021;22:959-69

[26] Cascetta P,Manzo A.RET inhibitors in non-small-cell lung cancer.Cancers2021;13:4415 PMCID:PMC8431193

[27] Hong DS,Kummar S.Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.Lancet Oncol2020;21:531-40 PMCID:PMC7497841

[28] Doebele RC,Paz-Ares L.trial investigatorsEntrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.Lancet Oncol2020;21:271-82 PMCID:PMC7461630

[29] O’Byrne KJ,Bondarenko I.Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study.Lancet Oncol2011;12:795-805

[30] Papadopoulos KP,Shaw AT.U.S. Phase I first-in-human study of taletrectinib (DS-6051b/AB-106), a ROS1/TRK inhibitor, in patients with advanced solid tumors.Clin Cancer Res2020;26:4785-94

[31] Lin JJ,Yoda S.Spectrum of mechanisms of resistance to crizotinib and lorlatinib in ROS1 fusion-positive lung cancer.Clin Cancer Res2021;27:2899-909 PMCID:PMC8127383

[32] Gainor JF,Yoda S.Patterns of metastatic spread and mechanisms of resistance to crizotinib in ROS1-positive non-small-cell lung cancer.JCO Precis Oncol2017;2017:PO.17.00063 PMCID:PMC5766287

[33] Awad MM,McTigue M.Acquired resistance to crizotinib from a mutation in CD74-ROS1.N Engl J Med2013;368:2395-401 PMCID:PMC3878821

[34] Zhang Y,Zeng L.Disease progression patterns and molecular resistance mechanisms to crizotinib of lung adenocarcinoma harboring ROS1 rearrangements.NPJ Precis Oncol2022;6:20 PMCID:PMC8971474

[35] Landi L,Heukamp L.Secondary ROS1 mutations and lorlatinib sensitivity in crizotinib-refractory ROS1 positive NSCLC: results of the prospective PFROST trial.Annals of Oncology2019;30:v609-10

[36] Wu X,Wan S.Investigation on the binding mechanism of loratinib with the c-ros oncogene 1 (ROS1) receptor tyrosine kinase via molecular dynamics simulation and binding free energy calculations.J Biomol Struct Dyn2018;36:3106-13

[37] Facchinetti F,Ammari S.Meningeal “lazarus response” to lorlatinib in a ROS1-positive NSCLC patient progressing to entrectinib.Cancer Manag Res2021;13:2805-10 PMCID:PMC8009349

[38] Drilon A,Wagner JP.A novel crizotinib-resistant solvent-front mutation responsive to cabozantinib therapy in a patient with ROS1-rearranged lung cancer.Clin Cancer Res2016;22:2351-8 PMCID:PMC4867287

[39] Katayama R,Togashi N.The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.Nat Commun2019;10:3604 PMCID:PMC6688997

[40] Katayama R,Friboulet L.Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.Clin Cancer Res2015;21:166-74 PMCID:PMC4286456

[41] Zhang S,Squillace R.The potent ALK inhibitor brigatinib (AP26113) overcomes mechanisms of resistance to first- and second-generation ALK inhibitors in preclinical models.Clin Cancer Res2016;22:5527-38

[42] Camidge DR,Tiseo M.Exploratory analysis of brigatinib activity in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer and brain metastases in two clinical trials.J Clin Oncol2018;36:2693-701

[43] Hegde A,Behrang A.Activity of brigatinib in crizotinib and ceritinib-resistant ROS1- rearranged non-small-cell lung cancer.JCO Precis Oncol2019;3:PO.18.00267 PMCID:PMC7410165

[44] Fujiwara Y,Yamamoto N.Safety and pharmacokinetics of DS-6051b in Japanese patients with non-small cell lung cancer harboring ROS1 fusions: a phase I study.Oncotarget2018;9:23729-37 PMCID:PMC5955103

[45] Lin JJ,Gupta P.Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition.NPJ Precis Oncol2020;4:21 PMCID:PMC7400592

[46] McCoach CE,Gowan K.Resistance mechanisms to targeted therapies in ROS1(+) and ALK(+) non-small cell lung cancer.Clin Cancer Res2018;24:3334-47 PMCID:PMC6050099

[47] Wu CH,Hsu CW,Lin CC.Small cell transformation in crizotinib-resistant ROS1-rearranged non-small cell lung cancer with retention of ROS1 fusion: a case report.Thorac Cancer2021;12:3068-71 PMCID:PMC8590892

[48] García-pardo M.ROS-1 NSCLC therapy resistance mechanism.Precis Cancer Med2021;4:16-16

[49] Shaw AT,Bang YJ.Crizotinib in ROS1-rearranged non-small-cell lung cancer.N Engl J Med2014;371:1963-71 PMCID:PMC4264527

[50] Shaw AT,Bang YJ.Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001.Ann Oncol2019;30:1121-6 PMCID:PMC6637370

[51] Wu YL,Kim DW.Phase II study of crizotinib in East Asian patients with ROS1-positive advanced non-small-cell lung cancer.J Clin Oncol2018;36:1405-11

[52] Michels S,Schildhaus HU.Safety and efficacy of crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS): a European phase II clinical trial.J Thorac Oncol2019;14:1266-76

[53] Remon J,Novello S.Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer.Cancer Treat Rev2021;95:102178

[54] Shaw AT,Bauer TM.Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.Lancet Oncol2017;18:1590-9 PMCID:PMC5777233

[55] Azelby CM,Bowles DW.ROS1 targeted therapies: current status.Curr Oncol Rep2021;23:94

[56] Lim SM,Lee JS.Open-label, multicenter, phase II study of ceritinib in patients with non-small-cell lung cancer harboring ROS1 rearrangement.J Clin Oncol2017;35:2613-8

[57] Cho BC,Bearz A.ASCEND-8: a randomized phase 1 study of ceritinib, 450 mg or 600 mg, taken with a low-fat meal versus 750 mg in fasted state in patients with anaplastic lymphoma kinase (ALK)-rearranged metastatic non-small cell lung cancer (NSCLC).J Thorac Oncol2017;12:1357-67

[58] Drilon A,Iyer S,Keddy C.ROS1-dependent cancers-biology, diagnostics and therapeutics.Nat Rev Clin Oncol2021;18:35-55 PMCID:PMC8830365

[59] Barlesi F,De Braud F.Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2.Annals of Oncology2019;30:II48-9

[60] Demetri G,Farago A.Efficacy and safety of entrectinib in patients with NTRK fusion-positive (NTRK-fp) tumors: pooled analysis of STARTRK-2, STARTRK-1 and ALKA-372-001.Annals of Oncology2018;29:viii713

[61] Doebele R,Siena S.OA02.01 efficacy and safety of entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC).J Thorac Oncol2018;13:S321-2

[62] Drilon A,Dziadziuszko R.trial investigatorsEntrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.Lancet Oncol2020;21:261-70 PMCID:PMC7811790

[63] Johnson TW,Bailey S.Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations.J Med Chem2014;57:4720-44

[64] Shaw AT,Chiari R.Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.Lancet Oncol2019;20:1691-701

[65] Zhu VW,Kim DW.An international real-world analysis of the efficacy and safety of lorlatinib through early or expanded access programs in patients with tyrosine kinase inhibitor-refractory ALK-positive or ROS1-positive NSCLC.J Thorac Oncol2020;15:1484-96

[66] Peled N,Kilickap S.GLASS: global lorlatinib for ALK(+) and ROS1(+) retrospective study: real world data of 123 NSCLC patients.Lung Cancer2020;148:48-54

[67] Sun TY,Chakraborty A,Wakelee HA.Lengthy progression-free survival and intracranial activity of cabozantinib in patients with crizotinib and ceritinib-resistant ROS1-positive non-small cell lung cancer.J Thorac Oncol2019;14:e21-4

[68] Ou SI,Shaw AT.Efficacy of taletrectinib (AB-106/DS-6051b) in ROS1 + NSCLC: an updated pooled analysis of U.S. and Japan phase 1 studies.JTO Clin Res Rep2021;2:100108 PMCID:PMC8474193

[69] Drilon A,Cho BC.Repotrectinib (TPX-0005) is a next-generation ROS1/TRK/ALK inhibitor that potently inhibits ROS1/TRK/ALK solvent- front mutations.Cancer Discov2018;8:1227-36

[70] Yun MR,Kim SY.Repotrectinib exhibits potent antitumor activity in treatment-naïve and solvent-front-mutant ROS1-rearranged non-small cell lung cancer.Clin Cancer Res2020;26:3287-95

[71] Cho BC,Doebele RC.Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1 fusion-positive non-small cell lung cancer (TRIDENT-1 study).JCO2019;37:9011-9011